|Bid||0.4000 x N/A|
|Ask||0.4200 x N/A|
|Day's Range||0.4200 - 0.4500|
|52 Week Range||0.2200 - 0.8500|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
TORONTO, November 22, 2023--Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending September 30, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted.
TORONTO, November 20, 2023--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Piper Sandler 35th Annual Healthcare Conference taking place November 28-30 in New York City.